Simulations Plus Inc - Company Profile
Powered by 
All the data and insights you need on Simulations Plus Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Simulations Plus Inc Strategy Report
- Understand Simulations Plus Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Simulations Plus Inc (Simulations Plus) develops and markets software for drug discovery and development for the pharmaceutical and biotechnology industries. The company develops absorption, distribution, metabolism, excretion and toxicity modeling and simulation software. The key products are Gastroplus, Manolix suite, DDDplus, NAFLDsym, IPFsym, ILDsym,RENAsym and CUSTOM QSP software.It provides preclinical and clinical pharmacometric consulting services to help its customers with regulatory submissions. Simulations Plus’ pharmaceutical and chemistry software is licensed to agrochemical, biotechnology, pharmaceutical and food industries, and regulatory agencies worldwide. It also offers training workshops and provides consulting services. It distributes products and offers services throughout the world. Simulations Plus is headquartered in Lancaster, California, the US.
Headquarters
United States of America
Address
42505 10th Street West, Lancaster, California, 93534-7059
Website
www.simulations-plus.com
Telephone
1 661 7237723
No of Employees
192
Industry
Medical Equipment
Ticker Symbol & Exchange
SLP (NASD)
Revenue (2023)
$59.6M
10.5%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
-20.2%
(2023 vs 2022)
Market Cap*
$912.3M
Net Profit Margin (2023)
XYZ
-27.8%
(2023 vs 2022)
* As of and is in US$
Simulations Plus Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| ADMET and Physiologically based Pharmacokinetic Modeling and Simulation Software: | Consulting Services |
| Gastroplus | Training and Workshops |
| Manolix suite | Modeling and Analysis/Simulation |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Research Grant | In September, the company recievced grant for validating and defining best practices for physiologically based biopharmaceutics/pharmacokinetics modeling workflows to simulate virtual bioequivalence (VBE) studies in support of regulatory biowaivers. |
| 2023 | Acquisitions/Mergers/Takeovers | In June, the company acquired Immunetrics, Inc., a modeling and simulation company. |
| 2023 | Others | In April, the company announced that the U.S. FDA had renewed the licenses of DILIsym software. |
Competitor Comparison
| Key Parameters | Simulations Plus Inc | Thermo Fisher Scientific Inc | Revvity Inc | NextGen Healthcare Inc | OmniComm Systems Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Lancaster | Waltham | Waltham | Irvine | Fort Lauderdale |
| State/Province | California | Massachusetts | Massachusetts | California | Florida |
| No. of Employees | 192 | 130,000 | 16,700 | 2,783 | 108 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Will Frederick | Chief Financial Officer | Executive Board | 2020 | 60 |
| Shawn M. O’Connor | Chief Executive Officer | Senior Management | 2018 | 64 |
| Scott Q. Siler | Chief Scientific Officer - Quantitative Systems Pharmacology | Senior Management | - | - |
| Viera Lukacova | Chief Scientific Officer - Simulation Plus | Senior Management | - | - |
| Walter S. Woltosz | Chairman | Non Executive Board | 2018 | 77 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer